Abstract
The neurotrophic factors play an important role in the maintenance of neurone viability and neuronal communication which are considered to be altered in schizophrenia. Subchronic application of ketamine (Ket) was found to be a useful model in schizophrenia research. To further validate this model the mRNA levels of neurotrophic factors NGF, NT- 3, and BDNF and their receptors TrkA, TrkB, and TrkC, respectively, were measured in different brain areas in Ketpretreated rats subchronically dosed with the atypical antipsychotic drug risperidone (Ris). With the exception of NGF in the frontal cortex, Ket pretreatment did change NGF, NT-3, and BDNF mRNA levels in the frontal cortex, the hippocampus, the striatum, the thalamus/hypothalamus region, and in the cerebellum. These changes correspond with changes at their tyrosine kinase receptors. Ris treatment normalised altered NT-3 levels in the hippocampus and balanced BDNF levels in the same structure. It was concluded that the Ket model might reflect distinct alterations in neurotrophic factor activity as found in schizophrenic patients and, moreover, that Ris treatment rebalances disturbed neurotrophic factor activity.
Keywords: Schizophrenia, ketamine, risperidone, neurotrophic factors, rat
Medicinal Chemistry
Title: Expression of mRNA of Neurotrophic Factors and their Receptors are Significantly Altered After Subchronic Ketamine Treatment
Volume: 4 Issue: 3
Author(s): Axel Becker, Gisela Grecksch, Herbert Schwegler and Thomas Roskoden
Affiliation:
Keywords: Schizophrenia, ketamine, risperidone, neurotrophic factors, rat
Abstract: The neurotrophic factors play an important role in the maintenance of neurone viability and neuronal communication which are considered to be altered in schizophrenia. Subchronic application of ketamine (Ket) was found to be a useful model in schizophrenia research. To further validate this model the mRNA levels of neurotrophic factors NGF, NT- 3, and BDNF and their receptors TrkA, TrkB, and TrkC, respectively, were measured in different brain areas in Ketpretreated rats subchronically dosed with the atypical antipsychotic drug risperidone (Ris). With the exception of NGF in the frontal cortex, Ket pretreatment did change NGF, NT-3, and BDNF mRNA levels in the frontal cortex, the hippocampus, the striatum, the thalamus/hypothalamus region, and in the cerebellum. These changes correspond with changes at their tyrosine kinase receptors. Ris treatment normalised altered NT-3 levels in the hippocampus and balanced BDNF levels in the same structure. It was concluded that the Ket model might reflect distinct alterations in neurotrophic factor activity as found in schizophrenic patients and, moreover, that Ris treatment rebalances disturbed neurotrophic factor activity.
Export Options
About this article
Cite this article as:
Becker Axel, Grecksch Gisela, Schwegler Herbert and Roskoden Thomas, Expression of mRNA of Neurotrophic Factors and their Receptors are Significantly Altered After Subchronic Ketamine Treatment, Medicinal Chemistry 2008; 4 (3) . https://dx.doi.org/10.2174/157340608784325124
DOI https://dx.doi.org/10.2174/157340608784325124 |
Print ISSN 1573-4064 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6638 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Functional Interactions of Tau and their Relevance for Alzheimers Disease
Current Alzheimer Research Intra and Extracellular Protein Interactions with Tau
Current Alzheimer Research Current Approaches for the Treatment with Thyroid Hormone Analogs
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Therapeutic Approaches to the Challenge of Neuronal Ceroid Lipofuscinoses
Current Pharmaceutical Biotechnology Recent Progress in Cerebrovascular Gene Therapy
Current Neurovascular Research PC9, A New Actor in Autosomal Dominant Hypercholesterolemia
Current Genomics SPECT Radiopharmaceuticals for Dementia
Current Radiopharmaceuticals Nongenomic Actions of Thyroid Hormones: Every why has a Wherefore
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Neurotrophic Factors for the Investigation and Treatment of Movement Disorders
Current Medicinal Chemistry - Central Nervous System Agents Phycobilins and Phycobiliproteins Used in Food Industry and Medicine
Mini-Reviews in Medicinal Chemistry Possible Neuroprotective Strategies for Huntingtons Disease
Current Neuropharmacology The Chemokine Receptor CXCR4 as a Therapeutic Target for Several Diseases
Mini-Reviews in Medicinal Chemistry Ethanol Metabolism and Effects: Nitric Oxide and its Interaction
Current Clinical Pharmacology Disorders of Consciousness and Pharmaceuticals that Act on Oxygen Based Amino Acid and Monoamine Neurotransmitter Pathways of the Brain
Current Pharmaceutical Design Capillary Electrophoresis with Mass Spectrometry: Applications to Metabolomic Analysis
Current Metabolomics Extranuclear Effects of Thyroid Hormones in Skeletal Muscle
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Quantitative Molecular Imaging of Neuronal Nicotinic Acetylcholine Receptors in the Human Brain with A-85380 Radiotracers
Current Medical Imaging Design of Iodine-Lithium-α-Dextrin Liquid Crystal with Potent Antimicrobial and Anti-Inflammatory Properties
Current Pharmaceutical Design Re-Examining the Need for Tissue Diagnosis in Pediatric Diffuse Intrinsic Pontine Gliomas: A Review
Current Neuropharmacology Neuron Protection as a Therapeutic Target in Acute Ischemic Stroke
Current Topics in Medicinal Chemistry